Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

About this update from Amneal Pharmaceuticals, Inc.

[{"type":"image","alt":"Knight Therapeutics","displaySize":"","headline":null,"caption":"Knight Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nIp9.tgiE4HLNmyfEs7DtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79}},"lazy":false},{"type":"text","content":"MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada.","length":279,"tagName":"p"},{"type":"text","content":"CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease. The innovative design of CREXONT® allows for rapid onset, while leveraging a mucoadhesive polymer for slow LD release, potentially enabling longer LD absorption in the gut. CREXONT® is expected to compete in a market size of over $50 million in Canada and over $120 million in Brazil. In each of these markets, the controlled release portion of the market was $15 million, during the twelve-month period ended on September 2024, according to IQVIA.","length":584,"tagName":"p"},{"type":"text","content":"In January 2024, Knight announced that it had entered into an agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal") for the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America. Knight is also working to submit the marketing authorization application in Mexico and Brazil during 2025.","length":357,"tagName":"p"},{"type":"text","content":""The submission of CREXONT® in Canada highlights Knight's ongoing commitment to enhancing our central nervous system (CNS) portfolio," said Samira Sakhia, President and CEO of Knight. "With a significant unmet medical need in Parkinson’s disease treatment, CREXONT® will offer a valuable new therapeutic option for the patients."","length":353,"tagName":"p"},{"type":"text","content":"About CREXONT®","length":14,"tagName":"p"},{"...

More updates from Amneal Pharmaceuticals, Inc.